News

HDA UK Media And Political Bulletin – 17 April 2018

Media and Political Bulletin

17 April 2018

Media Summary

MHRA will lose EMA work before Brexit transition period

The Pharmaceutical Journal, Alison Moore, 16 April 2018

 

The Pharmaceutical Journal reports that the UK will lose its involvement in evaluating medicines for the European Medicines Agency (EMA) from the date it formally leaves the European Union in March 2019, despite plans for the UK to remain closely tied to the European Union (EU) during a transition period lasting until the end of 2020.

The EMA has appointed new rapporteurs and co-rapporteurs for 370 centrally authorised products where the UK’s Medicines and Healthcare Regulatory Agency (MHRA) and the Veterinary Medicines Directorate had co-ordinated post-authorisation work.

Despite post-Brexit transition plans the EMA said the MHRA could no longer engage in “centralised regulatory procedures” after 29 March 2019 unless another date for Brexit is agreed.

You can find more information on the EMA website.

 

Parliamentary Coverage

House of Commons – Tabled Written Questions: Health and Social Care, 16 April 2018

 

Jeremy Lefroy MP: To ask the Secretary of State for Health and Social Care, what the timetable for negotiations on the new pharmaceutical price regulation scheme is; and if he will make a statement.

Anne Marie Morris MP: To ask the Secretary of State for Health and Social Care, with reference to the Health Service Medical Supplies (Costs) Act 2017, when he plans to bring forward legislative proposals to regulate the costs of specials dispensed in community pharmacies.

Paul Blomfield MP: To ask the Secretary of State for Health and Social Care, whether the UK will remain a member of the European Medicines Agency during the implementation period after the UK leaves the EU.

Paul Blomfield MP: To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications of the Medicines and Healthcare products Regulatory Agency being excluded from the European Medicines Agency during the implementation period after the UK leaves the EU.

 

Full Coverage

MHRA will lose EMA work before Brexit transition period

The Pharmaceutical Journal, Alison Moore, 16 April 2018

 

Despite plans to continue its close work with the EMA, the MHRA will lose involvement in evaluating medicines for the EU from March 2019.

The UK will lose its involvement in evaluating medicines for the European Medicines Agency (EMA) from the date it formally leaves the European Union in March 2019, despite plans for the UK to remain closely tied to the European Union (EU) during a transition period lasting until the end of 2020.

The EMA has appointed new rapporteurs and co-rapporteurs for 370 centrally authorised products where the UK’s Medicines and Healthcare Regulatory Agency (MHRA) and the Veterinary Medicines Directorate had co-ordinated post-authorisation work.

The new rapporteurs — who come from the other EU states plus Norway and Iceland — will take on full responsibility for the medicines on 30 March 2019, the day after the UK leaves the EU.

Despite post-Brexit transition plans the EMA said the MHRA could no longer engage in “centralised regulatory procedures” after 29 March 2019 unless another date for Brexit is agreed.

The MHRA said there has been no decision yet on the future relationship with the EMA. “We want to retain a close working partnership with the EU to ensure patients continue to have timely access to safe medicines and medical innovations. We are committed to continuing a close working relationship with the European Medicines Agency,” it said in a statement. “This was reiterated further by the Prime Minister in her Mansion House speech of 2 March, where she confirmed the government would like to explore with the EU the terms on which the UK could remain part of EU agencies, such as the EMA.”

It said it is considering the impact of the EMA decision, but that most of its regulatory work is national rather than EU. It would not comment on whether it had requested that that work remain with it post-Brexit.

Niall Dickson, co-chair of the Brexit Health Alliance, which includes the Academy of Medical Royal Colleges, the NHS Confederation, and the Association of the British Pharmaceutical Industry among its members, said: “Our shared approach to regulation has given patients throughout Europe faster access to treatment. The UK has been a significant player in shaping the current system and now we are leaving the EU we accept that is bound to change.

“The EMA’s decision that the UK will no longer be leading work assessing new medicines, therefore, comes as no surprise. But we very much hope that the UK and EU will reach an agreement which will enable us to participate more fully. We believe that would be in the interests of both sides.

Work on licensing and monitoring medicines has been one of the first areas to be directly affected by Brexit. In November 2017, the 27 remaining EU member states took the decision to relocate the EMA headquarters from London to Amsterdam.

HDA UK Media And Political Bulletin – 17 April 2018

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?